Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
SCLP
vs
F
FTSE All Share Index
SCLP
Over the past 12 months, SCLP has outperformed FTSE All Share Index, delivering a return of -10% compared to FTSE All Share Index's 0% growth.
Stocks Performance
SCLP vs FTSE All Share Index
Performance Gap
SCLP vs FTSE All Share Index
Performance By Year
SCLP vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Scancell Holdings PLC
Glance View
Scancell Holdings is a UK biotechnology company focused on making new cancer treatments, especially immunotherapies that help the body’s immune system find and attack tumors. Its main work is developing drug candidates in the lab and through clinical trials rather than selling finished medicines today. The company is built around a small number of proprietary platforms, including programs aimed at cancer and some infectious disease targets. Scancell’s customers are not patients in the usual retail sense. Its main business relationships are with hospitals and trial sites that run studies, research partners, and larger pharmaceutical companies that may license or collaborate on its science. It makes money mainly through research funding, collaboration income, and any future licensing or commercialization deals if its drug candidates are approved and adopted. What makes Scancell different is that it sits very early in the drug value chain: it is a research-driven developer that creates immune-based therapies and then tries to prove they work well enough to partner with a bigger drug maker or bring them to market. That means the company’s value depends on turning scientific ideas into medicines, not on manufacturing and selling large volumes of products itself.
